SANJYOT BHADKAMKAR: Open Payments
NPI 1457778961 · MOBILE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,935 in 152 payments from 38 companies in 2025. Trend: 2023 $2,923 · 2024 $4,236 · 2025 $3,935
Food & beverage: $2,935Long term medical supply or device loan: $1,000
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $1,217 |
| AstraZeneca Pharmaceuticals LP | 13 | $243 |
| Merck Sharp & Dohme LLC | 12 | $238 |
| Janssen Biotech, Inc. | 10 | $192 |
| PFIZER INC. | 10 | $187 |
| Regeneron Healthcare Solutions, Inc. | 6 | $141 |
| Celgene Corporation | 6 | $140 |
| Daiichi Sankyo Inc. | 6 | $138 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $132 |
| E.R. Squibb & Sons, L.L.C. | 6 | $116 |
Products named: KISQALI, KEYTRUDA, LIBTAYO, OPDIVO, REBLOZYL, IMFINZI, VERZENIO, ERLEADA.
Industry payments across AL — which companies pay providers there.
